anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Randomized, double-blind (blinded for trial subject and the study physician), placebo controlled clinical trial in parallel assignment of the immunogenicity, safety, and efficacy of the Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults.

The trial will include 2,000 volunteers over the age of 18. After screening, they will be randomised (3:1) into two groups - a reference group of 500 volunteers who will receive the placebo and a study group of 1,500 volunteers who will receive the combined Gam-COVID-Vac vaccine against SARS-induced coronavirus infection-СoV-2oV-2. The trial subjects will be randomized into five age strata: 18-30, 31-40, 41-50, 51-60 and 60+ years. Each subject will participate in the trial for 180±14 days after the first dose of the study drug/placebo and will have one screening visit and five on-site visits to the study physician during the said period. The study drug/placebo will be administered intramuscularly during vaccination visits 1 and 2 (day 1 and day 21±2). Follow-up visits Nos. 3, 4, 5 will be conducted on days 28±2, 42±2 and 180±14, respectively. Blood samples will be taken from certain subjects during the following visits to assess the immunogenicity parameters on days 1, 42±2 and 180±14. During observation visits, vital indicators will be assessed on all trial subjects and changes in the subjects' condition and well-being will be recorded, observational visits may be remote, using telemedicine (TM) technologies. Additionally, the trial subjects will be able to have remote consultations with the study physician through the TM. Data from trial subjects will be collected through electronic case report forms.
BACKGROUND: Medication safety issues occur frequently among older-adult patients with chronic diseases during the transition from the hospital to their homes. Patient participation in medication safety has been found to be an effective measure for improving patient safety. However, few studies have been conducted on the safety of older-adult patients with chronic disease during the hospital to family transition period. This study aimed to understand the experiences and perceptions of such patients regarding participation in medication safety during the hospital to family transition period and to explore the actual situation and obstacles during this period in the Chinese context.
METHODS: A descriptive, qualitative research approach was adopted using purposive sampling. Eighteen patients with chronic disease (aged 61-84 years) participated, all of whom were in the period of transition from hospital to home. Data were collected through semi-structured face-to-face interviews and analysed using directed qualitative content analysis.
RESULTS: Four themes and 12 sub-themes were identified in this study. The four themes were participation in medication decision-making, participation in medication self-management, participation support, and barriers to patient participation.
CONCLUSIONS: Patient participation is important in ensuring medication safety during the hospital to family transition period. This study highlights that older-adult patients' participation in medication safety includes three aspects: participation in medication decision-making, participation in medication self-management, and participation support. Health literacy, medical communication, and family care support are the key factors affecting patient participation in medication safety. Effective intervention strategies for this patient group during the transition period would target improving patients' cognition, health literacy, doctor-prescription communication, and family care support to encourage patients to be more actively involved in the process of drug treatment.
A process for the transformation of Burkholderia spp . (especially B.pseudomallei ) comprises:  (i) culture of the bacterial cells in the presence of an antibiotic at a level at which said cells remain viable; (ii) subjecting said cultured cells to electroporation in the presence of a transforming plasmid.  The antibiotic may be kanamycin, preferably in a concentration of 10 to 150 micrograms per ml. of culture medium. Electroporation may be effected using an applied voltage of from 1.4 to 1.8 kV (field strength of from 7 to 9 kV per cm.). The process may be used either to effect transposon mutagenesis or to inactivate genes by insertional mutation. The transformed bacterium may be incorporated into a vaccine, preferably in admixture with a pharmaceutically-active carrier.
Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Participants will receive double-blind Elagolix on Day 1 for 3 months. At month 4, participants will receive open-label elagolix in combination with COC (combined oral contraceptive) for 15 months. Participants will be followed-up for up to 12 months.
Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
The investigators plan to conduct a randomized, controlled clinical trial involving women with pelvic organ prolapse planning to have prolapse surgery with 1 of 4 fellowship-trained Urogynecologists at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center in Washington, DC. Women will be recruited prior to their preoperative counseling sessions during routine office visits and/or by telephone. After obtaining informed consent, women who agree to participate will be randomized to preoperative counseling sessions where an online risk calculator tool for the development of postoperative de novo stress urinary incontinence is or is not used. This tool is accessible at no cost from the following website: http://www.r-calc.com/ExistingFormulas.aspx?filter=CCQHS. At the time of these sessions, participants will decide whether to have a midurethral sling placed at the time of their prolapse repair to prevent development of stress urinary incontinence after surgery. After making this decision, all participants will complete the validated Satisfaction with Decision Scale to assess their satisfaction with their decision regarding midurethral sling placement. This validated 6-item self-administered questionnaire with a 5 point response scale takes approximately 3 minutes to complete. Participants will complete the Satisfaction with Decision Scale a second time at the time of their 2 week postoperative visit. Three months after surgery, participants will complete the Satisfaction with Decision Scale a third time, along with other validated quality of life questionnaires.
CYP2D6 Poor Metabolizers   
Approximately 7% of the normal population has a genetic variation that leads to reduced levels of activity of CYP2D6 isozyme. Such individuals have been referred to as poor metabolizers. After a single oral dose of 4 mg or 8 mg galantamine, CYP2D6 poor metabolizers demonstrated a similar Cmax and about 35% AUC∞ increase of unchanged galantamine compared to extensive metabolizers.  
  
A total of 356 patients with Alzheimer’s disease enrolled in two Phase 3 studies were genotyped with respect to CYP2D6 (n=210 hetero-extensive metabolizers, 126 homo-extensive metabolizers, and 20 poor metabolizers). Population pharmacokinetic analysis indicated that there was a 25% decrease in median clearance in poor metabolizers compared to extensive metabolizers. Dosage adjustment is not necessary in patients identified as poor metabolizers as the dose of drug is individually titrated to tolerability.
INTRODUCTION: Prophylactic antifungal therapy has been widely used for critical patients, but it has failed to improve patient prognosis and has become a hot topic. This may be related to disruption of fungal homeostasis, but the mechanism of fungi action is not clear. As a common pathway in critical patients, intestinal ischemia-reperfusion (IIR) injury is fatal and regulated by gut microbiota. However, the exact role of enteric fungi in IIR injury remains unclear.
OBJECTIVES: This is a clinical study that aims to provide new perspectives in clarifying the underlying mechanism of IIR injury and propose potential strategies that could be relevant for the prevention and treatment of IIR injury in the near future.
METHODS: ITS sequencing was performed to detect the changes in fungi before and after IIR injury. The composition of enteric fungi was altered by pretreatment with single-fungal strains, fluconazole and mannan, respectively. Intestinal morphology and function impairment were evaluated in the IIR injury mouse model. Intestinal epithelial MODE-K cells and macrophage RAW264.7 cells were cultured for in vitro tests.
RESULTS: Fecal fungi diversity revealed the obvious alteration in IIR patients and mice, accompanied by intestinal epithelial barrier dysfunction. Fungal colonization and mannan supplementation could reverse intestinal morphology and function impairment that were exacerbated by fluconazole via inhibiting the expression of SAA1 from macrophages and decreasing pyroptosis of intestinal epithelial cells. Clodronate liposomes were used to deplete the number of macrophages, and it was demonstrated that the protective effect of mannan was dependent on macrophage involvement.
CONCLUSION: This finding firstly validates that enteric fungi play a crucial role in IIR injury. Preventive antifungal treatment should consider damaging fungal balance. This study provides a novel clue to clarify the role of enteric fungi in maintaining intestinal homeostasis.
The present invention relates to a method to inhibit bacteria from adhering to a submergible surface. The method contacts the submergible surface with an effective amount of at least one fluorosurfactant to inhibit bacterial adhesion to the submergible surface. The present invention also relates to a method for controlling biofouling of an aqueous system. This method adds an effective amount of at least one fluorosurfactant to inhibit bacteria from adhering to a submerged surface within the aqueous system. This method effectively controls biofouling without substantially killing the bacteria fouling organisms. The fluorosurfactant used in the method of the invention is an anionic or nonionic fluorosurfactant selected from: R f  CH 2  CH 2  SCH 2  CH 2  CO 2  Li, (R f  CH 2  CH 2  O)P(O) (ONH 4 ) 2 , (R f  CH 2  CH 2  O) 2  P(O) (ONH 4 ), (R f  CH 2  CH 2  O)P(O) (OH) 2 , (R f  CH 2  CH 2  O) 2  P(O) (OH), R f  CH 2  CH 2  O (CH 2  CH 2  O) x  H, R f  CH 2  CH 2  O(CH 2  CH 2  O) y  H, R f  CH 2  CH 2  SO 3  H, or mixtures thereof. The group R f  is F(CF 2  CF 2 ) 3-8 , x varies from 2-20, and y varies from 2-20. The present invention also relates to a compositions containing a fluorosurfactant and useable in the above methods. The compositions comprise at least one fluorosurfactant in an amount effective to inhibit bacteria from adhering to submergible or submerged surfaces.
Hypertension is a disease that becomes a major problem of health. In 2008, 40% of adults aged 25 years above were diagnosed with hypertension. The mortality rate of the complications of hypertension reaches 9.4 million deaths worldwide each year. Hypertension is often called a ''silent killer'' because it often appears without symptoms until it becomes severe and impacts on other organs. Hypertension affects both on physical and psychological. Several studies have found that hypertension can cause anxiety. Hypertension requires comprehensive pharmacological and non-pharmacological treatment. Since 1983, the World Health Organization has suggested the use of the non-pharmacological approach in hypertension treatment. Progressive Muscle Relaxation (PMR) is one of the therapies that is mostly used in complementary therapy and alternative medication. PMR is a technique developed by Edmund Jacobson in 1920. This technique is designed to create a state of physiological and psychological relaxation in patients. It requires the patient to tense and relax various muscle groups while focusing awareness on proprioceptive and interceptive sensations. Several studies have found that PMR exercise helps to reduce blood pressure. Besides, PMR exercise can also reduce anxiety in various diseases.

Study design will be randomized controlled trial. Study will be conducted at Life care Hospital Gujranwala. Written informed consent will be obtained. Patients will be allocated randomly. Subjects meeting the predetermined inclusion and exclusion criteria . Questionnaire will be used as subjective measurements of activity of daily living and Bp will be monitored for initial readings.subjects will be divided into two groups both groups will perform 30 minutes walk as baseline treatment. only one group will receive Jacobsons muscle relaxation technique. Patients will be demonstrated with the technique to contract and relax various groups of muscles, to coordinate contractions and relaxations with deep breaths and to perform the entire procedure with eyes closed in supine lying down position. Every subject will perform this supervised relaxation for 6 repetitions during a single session on once a day basis for four weeks. At the end of 4 weeks of treatment session blood pressure will be recorded questionnaire will be filled. The data thus obtained will be considered for statistical analysis
The present invention relates to a new sulfonation dehydrogenation abietate and a preparing method and the use thereof. The sulfonation dehydrogenation abietate can be used for treating diseases, such as digestive canal ulcer, acute gastritis, chronic gastritis, erosive gastritis, etc. The sulfonation dehydrogenation abietate is shown in the general formula (1) (disclosed in the specification), wherein R is Bi(OH) <++>, or 2BiO, or 1/2ZnH. Industrial calcined rosin calcium is used as raw materials which are treated through acid and alkaline; organic solvents are used for extracting and preparing abietic acid having less isomers, palladium/carbon catalyzing indexing dehydrogenation is used for preparing dehydrogenation abietic acid which is soufonated and recrystallized to produce pure sulfonation dehydrogenation abietic acid. The sulfonation dehydrogenation abietic acid is made into single zinc salt, double zinc salt and bismuth salt of the sulfonation dehydrogenation abietic acid according to an acid and alkali neutralizing principle or a salt replacing principle. The made salt can be used for preparing medicine for treating digestive canal ulcer and gastritis.
The invention discloses traditional Chinese medicine preparations used for treating hemorrhoids and anal fissure. The preparations are prepared from the medicine materials of, by weight: 20-35 parts of Japanese pagodatree fruit, 6-15 parts of longleaf garden burnet root, 6-18 parts of Japanese pogodatree flower, 6-16 parts of honeysuckle flower, 6-15 parts of Chekiang fritillary bulb, 4-15 parts of angelica archang lica, 4-12 parts of balloonflower root, 6-18 parts of glabrous greenbrier rhizome, and 4-12 parts of artemisia capillaries. The medicine can be prepared into powders, capsule preparations, tablets, instant granules, and oral liquid preparations. The medicine materials selected by the invention have functions of blood cooling, bleeding stopping, heat clearing, dampness removing, swelling subsiding, pus discharging, stagnation eliminating, and detoxifying. The medicine preparations are used for treating hemorrhoids and anal fissure with a variety of causes. As a result of clinical applications, the medicine preparations have the advantages of low treatment cost, no toxic or side effect, and good treatment effect.
Arm 1 (n=120) received metformin+sibutramine p. o., 1 tablet (850 mg + 10 mg) once per day. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.
BACKGROUND: Although endovascular treatment of venous obstruction with percutaneous transluminal angioplasty (PTA) and stenting is a safe and effective alternative to conservative treatment, the overall prevalence of in-stent restenosis (ISR) remains high in this patient population. This study reports a novel treatment option for patients with chronic ISR (C-ISR).
METHODS: At our center, all patients with ISR were treated based on the time since the initial intervention. Acute in-stent restenosis (A-ISR) was preferably treated with catheter-directed thrombolysis or a pharmacomechanical peripheral thrombectomy device and PTA. Selected patients with chronic ISR (C-ISR) (greater than 30 days) were treated with a catheter- guided unidirectional atherectomy in addition to PTA, under the assumption of a non-thrombotic mechanism in the development of C-ISR.
RESULTS: We demonstrate a safe and practical treatment option for chronic ISR using a catheter- guided technical approach with the Phoenix atherectomy device in four patients. Technical success was achieved in every case, and mid-term patency was restored in three out of four patients.
CONCLUSIONS: Restenosis following venous stenting is highly complex. Patients must be treated individually, with a focus on anticoagulation and antiplatelet therapy regimens, as well as the appropriate interventional treatment. Catheter- guided atherectomy is a viable option for this heterogeneous group of patients. Further studies are required to understand the etiology of chronic ISR.
INTRODUCTION: Itch can be reduced by pain. Activation of sleeping nociceptors (CMi) is a crucial mechanism for the peripheral component of intense and long-lasting pain. Thus, activation of CMi might be especially effective in itch reduction. Electrical stimulation using sinusoidal pulses activates CMi with tolerable pain intensity, whereas short rectangular pulses with low intensity do not. In humans, histaminergic itch is mediated by histamine-sensitive CMi, whereas other pruritogens activate polymodal nociceptors (CM).
METHODS: In a psychophysical approach in a balanced crossover repeated-measures design in healthy volunteers, we activated nociceptors by two different electrical stimulation paradigms via a matrix electrode: 4 Hz sinusoidal pulses that activate C-nociceptors including CMi or 4 Hz rectangular stimuli to activate nociceptors excluding CMi. After 5-min stimulation, itch was induced by either histamine iontophoresis or application of cowhage spicules. Itch ratings were assessed via a numerical rating scale (NRS).
RESULTS: Electrical 4 Hz sine wave stimulation (0.1 mA) with low pain ratings of 1.5 (NRS; 0-10) induced an axon reflex erythema (3 cm2 ), indicating activation of CMi, whereas rectangular 0.2 ms pulses (average 0.91 mA) with the same pain rating did not. Both electrical stimulation paradigms reduced itch magnitude over time evoked by either histamine or cowhage to a similar extent. Peak maximum itch evoked by histamine was reduced by both stimulation paradigms, but not cowhage maximum itch.
DISCUSSION: Since electrical stimulation with the rectangular pulse paradigm reduces itch to a similar extent as the sine wave stimulation paradigm, the input of CMi is not necessarily required for itch suppression. The input of A-fibres and polymodal nociceptors, similarly, as also achieved by scratching, seems to be sufficient for both forms of chemically evoked itch.
SIGNIFICANCE: Since activation of CMi does not provide additional benefit for itch suppression, spinal pain pathways transmitted via CM versus CMi have differential effects on itch-processing circuits. This is important knowledge for using electrical matrix stimulation as itch suppressor since activation of sleeping nociceptors either requires significantly painful stimulation paradigms or specialized stimulation paradigms as sinusoidal pulses. An alternative approach using half-sine wave pulses with low pain intensity activating specifically polymodal nociceptors to suppress itch via matrix electrode stimulation may be considered.
Neuromuscular junction (NMJ) degeneration is one of pathological factors of sarcopenia. Low-magnitude high-frequency vibration (LMHFV) was reported effective in alleviating the sarcopenia progress. However, no previous study has investigated treatment effects of LMHFV targeting NMJ degeneration in sarcopenia. We first compared morphological differences of NMJ between sarcopenic and non-sarcopenic subjects, as well as young and old C57BL/6 mice. We then systematically characterized the age-related degeneration of NMJ in SAMP8 against its control strain, SAMR1 mice, from 3 to 12 months old. We also investigated effects of LMHFV in SAMP8 on the maintenance of NMJ during the onset of sarcopenia with respect to the Agrin-LRP4-MuSK-Dok7 pathway and investigated the mechanism related to ERK1/2 signaling. We observed sarcopenic/old NMJ presented increased acetylcholine receptors (AChRs) cluster fragmentation and discontinuity than non-sarcopenic/young NMJ. In SAMP8, NMJ degeneration (morphologically at 6 months and functionally at 8 months) was observed associated with the sarcopenia onset (10 months). SAMR1 showed improved NMJ morphology and function compared with SAMP8 at 10 months. Skeletal muscle performance was improved at Month 4 post-LMHFV treatment. Vibration group presented improved NMJ function at Months 2 and 6 posttreatment, accompanied with alleviated morphological degeneration at Month 4 posttreatment. LMHFV increased Dok7 expression at Month 4 posttreatment. In vitro, LMHFV could promote AChRs clustering in myotubes by increasing Dok7 expression through suppressing ERK1/2 phosphorylation. In conclusion, NMJ degeneration was observed associated with the sarcopenia onset in SAMP8. LMHFV may attenuate NMJ degeneration and sarcopenia progression by increasing Dok7 expression through suppressing ERK1/2 phosphorylation.
PURPOSE:To provide a detergent which can improve the safety to the human body and the environment, detergency, and economy, which comprises a decomposition product of a protein derived from a particular grain as an active ingredient. CONSTITUTION:An aq. soln. or an aqueous dispersion (a) contg. 2-40wt.% protein derived from a grain, such as wheat gluten, corn gluten or soybean protein, is stirred at 60-180 deg.C for 10-60min in the presence of an alkali (b) (e.g., NaOH), thereby conducting the decomposition of component (a) with component (b). Then, the product is stirred at 60-120 deg.C for 10-600min in the presence of an acid (c). A partial decomposition product (A) having a wt.-average MW of 500-30,000 is prepd. by decomposition with component (c) and/or with an enzyme (d) having a protease activity at an optimum pH of the enzyme at 10-60 deg.C for 60-600min and/or with component (D) in the presence of a reducing agent of an oxidizing agent (e) at 10-100 deg.C for 10-600min. If necessary, component (A) is blended with a surfactant (B) in a component A to component B wt. ratio of 1-4:4-1.
A method is described whereby dendritic cells derived from the CD34+ and CD 34−hematopoietic cell lineages are directed to become programmable antigen presenting cells. The programmed cells may be pulsed with tumor cell RNA or tumor cell RNA expression products. The protocol provides for directing the maturation of dendritic cells to become antigen presenting cells. The protocol further provides for isolating tumor cell RNA from biopsy material that has been prepared in paraffin block storage. The directed dendritic cell is provided with a plurality of tumor markers by using tumor RNA in toto, the poly A+RNA fraction or the expression product of such RNA. Once activated the dendritic cells are incubated with T4 and T8 lymphocytes to stimulate and sensitize the T lymphocytes which upon introduction either into a donor host or a nondonor recipient will provide immune response protection.